This study focused on the regulation and affinity modulation of angiotensin II (Ang II) binding to its receptor subtypes (AT 1 -and AT 2 -receptor) in the coronary endothelium (CE) and cardiomyocytes (CM) of Sprague-Dawley male rats in normal (N), normal treated with losartan (NL), streptozotocininduced diabetic (D), insulin-treated diabetic (DI), losartan-treated diabetic (DL), and diabetic co-treated with insulin and losartan (DIL). Heart perfusion was used to estimate Ang II binding affinity (τ=1/k -n ) to its receptor subtypes on CE and CM. Diabetes decreased τ value on CE and increased it on CM as compared to normal. In DL group, the τ value decreased on CE but was normalised on CM. Insulin treatment alone (DI) or with losartan (DIL) restored τ to normal on both CE and CM.Western blot results for AT 1 -receptor density showed an increase in diabetics compared to normal with no normalising effect with insulin treatment.The AT 1 -receptor density was normalised in the diabetic groups treated with losartan +/-insulin. Results for AT 2 -receptor regulation revealed a significant difference between untreated (D) and losartan-treated (DL, DIL) diabetic groups.All of these data show the interrelated pathway and cross-talk between insulin and Ang II system indicating potentially negative effects on the diabetic heart.
Introduction
Angiotensin II (Ang II) is a potent vasoconstrictor that aids in blood pressure (BP) regulation as well as body fluid balance maintenance. On the heart, acting in both an endocrine and paracrine fashions 1 Ang II regulates contractility, remodelling, growth, apoptosis, and reduces cell coupling and conduction velocity in cardiac muscles. 2, 3 In addition, Ang II maintenance of body water and electrolyte homeostasis influences stroke volume. 4 Ang II has two major receptor subtypes, the Ang II type 1 receptor (AT 1 -receptor) and the Ang II type 2 receptor (AT 2 -receptor). The Ang II receptor subtypes exist in various peripheral tissues including the brain and the heart. 5, 6 Although both these receptor subtypes were found in cardiac muscle cells, 3, 7 the AT 1 -receptor was found to mediate most classical cardiovascular functions of Ang II such as BP elevation, vasoconstriction, aldosterone release, renal absorption of water and sodium, and catecholamine release facilitation. 3 AT 1 -receptor can be considered as a G protein coupled receptor (GPCR) since it is mainly coupled to a G q/11 protein and phospholipase C, as well as other G proteins and several tyrosine kinase pathways. 8 The stimulation of phospholipase C, the mobilisation of Ca 2+ , and the phosphorylation of MAP-kinases are some of its intracellular effects in cardiomyocytes. 7 The AT 2 -receptor subtype is coupled to a Gi protein activating the various tyrosine phosphatases and inhibiting many protein kinases. This leads to a negative regulation of the extracellular regulated kinase 2 (ERK2), which is activated by AT 1 -receptor signalling cascade. Therefore, AT 2 -receptor mediated effects seem to be antagonistic to AT 1 -receptor signalling cascades. 3, 9 While AT 1 -receptor mediated effects seem to have deleterious cardiovascular alterations, the AT 2 -receptor appears to have many cardioprotective influences. 10 According to a novel study AT 2 -receptor, by stimulation by Ang II, was found to up-regulate the expression of endothelial NO Synthase (eNOS) in neonatal rat cardiomyocytes, which in turn, helps antagonise the AT 1 -receptor induced upregulation of reactive oxygen species. 11 Diabetes mellitus (DM) is a disease characterised by chronic hyperglycaemia due to a partial or complete defect in insulin secretion as in type 1 diabetes and/or insulin action as in type 2 diabetes; 12, 13 however, its chief causes of morbidity and early death are cardiovascular diseases mainly coronary artery disease (CAD) and chronic heart disease. 13, 14 DM generates severe premature macrovascular anomalies, causing arteriosclerosis and atherosclerosis, and microvascular complications, leading to nephropathy, retinopathy, neuropathy, and small artery occlusion in the heart. 14, 15 Cardiomyopathy, a specific heart muscle dysfunction that occurs independently of CAD, may lead to heart failure. 14 16 This phenomenon was found to be due to a cascade of events initiated by insulin binding to its tyrosine kinase receptor. 16, 17 Insulin actions are mediated through binding to its tyrosine kinase receptor leading to tyrosine phosphorylation of many proteins, including the insulin receptor substrates IRS-1 and IRS-2. 17 Recent evidence indicates that G-protein coupled receptors, like the AT 1 -receptor and the AT 2 -receptor, may mimic the effects of receptors acting through tyrosine kinase, such as the insulin receptors, thus resulting in a complex cross-talk between the insulin and Ang II signalling pathways. 18, 19 This link was further emphasised by the use of losartan, an Ang II selective AT 1 -receptor blocker (ARB) used clinically as an antihypertensive drug. 20, 21 Our previous experiments on STZ-induced diabetic rats indicated that the co-treatment with insulin and losartan was almost able to totally prevent myocardial remodelling; 16 moreover, it improved the cardiac contraction as well as coronary blood flow in these diabetic rats through the modification of the affinity of Endothelin-1 (ET-1) to its receptor subtypes ET A -receptor and ET B -receptor. 16, 22 ET-1 is a potent vasoconstrictor most abundant in the systemic circulation. It mediates its effects via the ET A -receptor, the ET B -receptor, and the ET C -receptor subtypes which are also considered as G protein coupled receptors. 23, 24 Lately, several studies confirmed the interaction between ET-1 and Ang II via the AT 1 -receptor. 25 In DM, just as the renin-angiotensin-aldosterone system (RAAS), the ET-1 system is over activated aiding in the development of diabetic cardiovascular complications. 26 Moreover, ET-1 and Ang II, via almost the same pathways, antagonise the growth factor effects of insulin. For example, both ET-1 and Ang II were found to decrease the association between the insulin receptor substrates (IRS-1, IRS-2) and the p85 subunit of the PI3-kinase thus decreasing its activity and intervening with the insulin signalling cascade. 27, 28 In this study, we tried to determine the effects of the co-treatment of insulin and losartan on the modulation of Ang II receptor subtypes AT 1 -receptor and AT 2 -receptor in the hearts of diabetic rats using heart perfusion technique to assess Ang II binding affinity to its receptors on endothelial cells and cardiomyocytes, as well as western blotting to determine the density of these receptors.
Material and methods
All experiments were conducted with prior approval of the 'Institutional Review Board/Animal House Committee' of the American University of Beirut (AUB-MC). Experimental animals were handled, treated, and sacrificed in accordance with the guidelines of the 'American Association for Laboratory Animal Sciences (AALAS)' on 'Humane Care and Use of Laboratory Animals'.
Study design and methods

Treatment modality
To induce diabetes, rats were injected with STZ (85 mg/kg body mass) in the tail vein once. Nonfasting blood sugar which was greater than 250 mg/dL three days later indicated diabetes. Male Sprague-Dawley rats (mass 175-250 g) were distributed into six separate groups (N=36/group): normal group (N), normal group treated with losartan (NL), diabetic group (D), diabetic group treated with insulin (DI), diabetic group treated with losartan (DL), and diabetic group co-treated with insulin and losartan (DIL). Body masses and sugar levels were measured on a weekly basis. Losartan 50 mg tablets were crushed and homogenised in 100 ml water, and 0.7 mg/kg dose was given by oral gavage to each rat daily. Bovine insulin powder was dissolved in normal saline solution (NSS) (0.28 units/cc of NSS), and 1 unit/kg body weight was given intraperitoneally, twice daily.
Procedures
Heart perfusion
Each of the groups was further divided into two subgroups: The first (N=8) was perfused only with buffer; the second (N=8) was perfused with 20 mmol/L of 3-[(3-cholamidopropyl) dimethylammonio]-1-propanesulfonate (CHAPS; Sigma Chemical Company, St. Louis, MO) to slough off the endothelial lining. The rats were weighed, then anaesthetised by an intraperitoneal injection of sodium pentobarbital (50 mg/kg body weight) and each one was fixed to a heating pad to prevent rapid cooling. Then, the whole thoracic cavity was fully exposed to perform heart perfusion with the [I 125 ]-Ang II. This method was used in order to determine the binding kinetics of Ang II to its receptor subtypes at the level of the coronary endothelium (CHAPS-untreated rats) and the cardiomyocytes (CHAPS-treated rats).
Tissue preparation for histological studies
The hearts were flushed with NSS until they were cleared out of blood. The washed hearts were injected in situ with about 1 ml of cold isopentane through the apex while still beating, and, then removed and snap frozen in the same solution (isopentane/dry ice). Each heart was then cut, starting at the apex, into four blocks by three planes parallel to the base. Protein bands were then transferred for three hours on nitrocellulose membranes (Transblot unit, PowerPac HC, Bio-Rad Laboratory, CA, USA). The membrane was blocked with a blocking buffer for one hour then incubated overnight in a cold room with the primary polyclonal antibody; polyclonal AT 1 -receptor and AT 2 -receptor antibodies raised in rabbit (diluted 1/500 Santa Cruz Biotech., CA, USA). The primary antibody was removed from the membrane by three consecutive washes with Tris/Tween solution. This was followed by incubating for two hours with the secondary antibody, anti-rabbit IgG-HRP 20 (diluted 1/500 Santa Cruz Biotech., CA, USA), then washing the membrane with a Tris/Tween solution (four times). Blotted bands were detected by ECL (Enhanced Chemiluminescence) and developed on a Fuji Medical X-ray film (Fuji Photo Film Co., LTD, Tokyo, Japan) by autoradiography (Fisher Scientific, Pittsburg, USA). Band thicknesses were determined by a semi-quantitative densitometric analysis (arbitrary unit) using dedicated computer software, and expressed as mean of thickness±SEM.
Western blotting
Data analysis and statistical evaluation
All data were expressed as mean values obtained for all the parameters mentioned above, per animal and per group. To evaluate significance among different experimental groups, the student's t-test and the analysis of variance for multiple factors using the Bonferroni correction method were used. Values were expressed as arithmetic means±SEM. The degree of significance was judged by p values when necessary, where a p value <0.05 indicated significance.
Results
Body weights and plasma glucose levels
The mean body weights, the mean heart weights, and their ratio for the six different rat groups are represented in table 1. There is a significant decrease in the body weights of all the diabetic rat groups (D, DI, DL, DIL). In addition, our data show an increased heart weight to body weight ratio in all the diabetic groups The mean plasma glucose levels are represented in table 2. There was a significant increase in the plasma glucose levels of all diabetic rat groups (D, DI, DL, DIL) when compared to the normal rat groups (N, NL).
Heart perfusion results
Time-dependent radioactive Ang II ([ 3 H]-Ang II) concentration binding curves of normal and diabetic rats, whether treated or not, were mathematically curve-fitted using a first-order Bessel function physical model describing a 1:1 stoichiometry for reversible binding of Ang II Paper Table 1 Body weights and heart weights of the six rat groups. The results were considered significant at p<0.05. 
Rat group
Table 2
Plasma glucose levels of the six rat groups. The results were considered significant at p<0.05. 
Rat group
Western blot analysis
Western blotting analysis was performed on the experimental group (DIL) and compared to the other five different groups. Band thickness was resolved by a semi-quantitative densitometric analysis (arbitrary unit) using a dedicated computer program. Results for the DIL group and the other groups were expressed as the bands thickness average±SEM. Compared to the normal group (N), a significant increase in AT 1 -receptor density is noted in the following groups: normal treated with losartan group (NL), untreated diabetic group (D), and the insulin-treated diabetic group (DI). Moreover, AT 1 -receptor expression was found to be almost normalised in the losartan-treated diabetic group (DL), and the losartan and insulin co-treated diabetic group (DIL) ( figure 1 ). Regarding the AT 2 -receptor and comparing its expression in the normal group (N) to other groups, a significant increase in its density in the normal-treated with losartan group (NL), and a significant decrease in its density in the losartan-treated diabetic group (DL), and the losartan and insulin co-treated diabetic group (DIL) is apparent ( figure 2 ).
Discussion
Cardiovascular disorders are one of the major complications in diabetes. 13 Our previous findings reported that losartan, an ARB, in diabetic normotensive rats supplemented with insulin was able to prevent the myocardial degeneration caused by diabetes. 16 We also showed that supplementation with insulin and administration of pharmacologic doses of losartan could improve cardiac contraction as well as coronary blood flow in the same model, through the Paper Table 3 The calculated kinetic parameters of Ang II binding to its receptors at the coronary endothelium. (1, 3), (1, 5) , (2, 3) , (3, 4) , (3, 5) , (3, 6) , (4, 5) , (5, 6) are significant (p<0.05).
Rat group
Table 4
The calculated kinetic parameters of Ang II binding to its receptors at the cardiomyocytes level (CHAPS-treated). Ang II was found to be up-regulated in the diabetic state, 20, 21 and seems to contribute to the cardiovascular complications through its action on the G protein coupled AT 1 -receptor. 30 In this study, we attempted to uncover the effects of the co-treatment of insulin and losartan on the modulation of Ang II receptor subtypes AT 1 -receptor and AT 2 -receptor in STZ-induced diabetic rat hearts. These results were correlated with the general effects of Ang II selective AT 1receptors blockers and insulin on cardiac function. Finally, the information obtained helped us further illuminate the complex cross-talk between insulin, Ang II, and ET-1 at the level of the cardiovascular system in normal and diabetic states.
Rat group
Western blotting of Ang II receptor subtypes from the rat heart tissue was used to assess the variation in their relative densities among the different treatment groups. Results for the AT 1 -receptor subtype (figure 1), known for its negative effects on the heart tissue in disease states, showed an increase in its density in diabetes (D), compared to the normal (N), confirming previous studies of its relation to the deleterious cardiovascular alterations seen in diabetes, among which are the up-regulation of the RAAS 21 and AT 1 -receptor expression. 31, 32 However, insulin supplementation in diabetes (DI) had no normalising effect with respect to this receptor density. Interestingly, AT 1 -receptor density was normalised in the diabetic groups treated with losartan +/-insulin, suggesting that the blockade of the AT 1 -receptor in diabetic rats could diminish the negative effects related to this receptor subtype up-regulation in diabetes. Moreover, these results show that in the normal losartan-treated state (NL) and in the presence of systemic insulin, losartan increased AT 1 -receptor density contrary to its action in the absence of insulin (DL). This leads us to say that the crosstalk between insulin and AT 1 -receptor subtype is crucial for the latter's density regulation.
On the other hand, western blot results for the AT 2 -receptor subtype (figure 2) revealed a significant up-regulation of this receptor density in the losartan-treated normal group (NL) as compared to the normal (N). The increase in this receptor density can also be seen in the diabetic group confirming earlier studies that also reported this up-regulation in diabetes. 33 Also, one can note the significant difference between the untreated diabetic group (D) and the losartan-treated diabetic groups (DL, DIL) on one hand, and between the normal group (N) and the losartan and insulin co-treated diabetic group (DIL) on the other. Therefore, these results also hint at the interrelated pathways between insulin and the AT 2 -receptor subtype.
The results of the receptor density analyses may at least partly explain the molecular basis of the beneficial effect of losartan and insulin cotreatment in diabetic rat hearts. Therefore, lack of insulin in diabetes leads to an elevated level of Ang II 34 which can trigger an up-regulation of both receptor subtypes. Also, insulin administration alone in diabetic rats can normalise the AT 2 -receptor density but could not alter that of the AT 1 -receptor. On the other hand, losartan treatment could restore the densities of both receptor subtypes to their normal state. Moreover, the co-treatment with both insulin and Western blot expression of the AT 2 -receptor in rat heart tissue protein homogenate. The AT 2 -receptor density increased in the NL group compared to the N group; moreover AT 2 -receptor expression decreased in the DL and DIL groups (p<0.05). However, no expression differences were observed between the N, D, and DI groups. Finally, the elevated Ang II receptor subtypes densities seen in the normal rats treated with losartan can be explained by the fact that when the Ang II systemic levels are normal and the AT 1 -receptors are blocked, the cell up-regulates the Ang II receptor subtypes expression in order to maintain the physiologic functions of the AT 1 -receptor. In addition, this observation is confirmed by several studies which reported that in normal conditions Ang II usually inhibits AT 1 -receptor mRNA expression via the AT 1 -receptor 35, 36 and logically if this receptor is blocked, the inhibition is removed and thus the AT 1 -receptor expression would increase.
The function of the receptor can be influenced not only by its amount but also its affinity. Hence, a rat heart perfusion method was used in order to determine the binding affinity (residency time constant, τ) of Ang II to its receptor subtypes both at the level of the coronary endothelium (CHAPS-untreated rats) and the cardiomyocytes (CHAPS-treated rats). Using a physicalmathematical model, 29 heart perfusion results showed that Ang II affinity to its receptor subtypes decreases significantly in diabetes (D) at the level of the coronary endothelium (table 3) and that insulin treatment to the diabetic groups (DI, DIL) was able to restore the affinity back to normal. Using these data, one could say that insulin is the key player in Ang II-receptor binding modulation, through losartan treatment in diabetes (DL) which was able to semi-restore the affinity back to normal. Therefore, and once again, the cross-talk between insulin and the Ang II receptors seem to have an influence on Ang II binding kinetics on coronary endothelial cells. On the other hand, at the level of cardiac myocytes (CHAPS-treated), in the diabetic state there is an increase in the Ang II receptor subtypes affinity when compared to the normal (table 4 ). In addition, at this same level one can note the difference between the untreated diabetic group (D) and the insulin-treated diabetic groups (DI, DIL), re-emphasising the role of insulin in Ang II binding affinity regulation. Overall, the increased Ang II affinity to its receptors at the cardiomyocyte level can be considered as one of the deleterious alterations imposed by diabetes on the heart, given the inherent negative effects of Ang II on cardiovascular integrity and function in diseased states. 4, 34 By contrast, insulin and/or losartan treatment was able to reduce this affinity and thus diminish the undesirable effects of diabetes with respect to Ang II receptor subtype affinity modulation.
In summary, our results are in harmony with other studies revealing that the diabetic state is characterised by extensive changes in Ang II signal transduction, translated via the modulation of its two receptor subtypes. Insulin and losartan co-administration to diabetic rats may improve cardiac function through the reversal of the negative effects of diabetes on the cardiovascular actions of Ang II. The actions of losartan can be beneficial in the regulation of the Ang II receptor subtypes, where insulin actions focus on the modification of the affinity of Ang II to its receptor subtypes at the level of CEs and cardiomyocytes. These modifications occurring at the Ang II system level are likely to be in conjunction and in direct relation to the alterations in both the insulin and the endothelin systems seen in our previous studies, reinforcing the presence of a complex cross-talk among the Ang II, the ET-1, and the insulin systems. In essence, losartan administration to this rat model of insulin dependent diabetes mellitus seems to be beneficial in reversing the diabetic cardiovascular alterations and thus maintaining this system's integrity.
Conclusions
Cardiovascular diseases are the main cause of morbidity in diabetic patients. There are many factors acting in the pathogenesis of macrovascular and microvascular complication in diabetes. The cross-talk between insulin and the Ang-II can help us explain and add insight into the management of these negative effects of diabetes on the heart. 
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